News

J&J's ICOTYDE meets Phase 3 goals head-to-head against injectable in plaque psoriasis

What's the update? On 6 November 2026, Johnson & Johnson Innovative Medicine reported positive results from ICONIC-ASCEND, the first-ever head-to-head Phase 3 trial comparing an oral pill against an injected biologic in moderate-to-severe plaque psoriasis. ICOTYDE (icotrokinra), a once-daily oral peptide that blocks the IL-23 receptor, was tested against placebo and the injectable biologic ustekinumab in adults and adolescents aged 12 and older.

The results: The trial met both co-primary endpoints at week 16: 55.2% of ICOTYDE patients achieved PASI 90 — at least a 90% improvement in the area and severity of their psoriasis — versus 3.6% on placebo, and 70.4% achieved clear or almost clear skin (IGA 0/1) versus 9.5% on placebo. Against ustekinumab, ICOTYDE achieved non-inferiority on key secondary endpoints at week 28 with numerically higher skin-clearance rates, and in patients new to systemic treatment it delivered 48.1% complete skin clearance (PASI 100) versus 31.2% for ustekinumab (nominal p=0.028). No new safety signals were identified.

Why it matters: The results reinforce ICOTYDE as a potential first-line systemic therapy for plaque psoriasis, offering an oral alternative in a category long dominated by injectable biologics. ICOTYDE was jointly discovered with Protagonist Therapeutics under a licence and collaboration agreement, with J&J holding exclusive worldwide development and commercialisation rights from Phase 2 onwards.

Read more: Johnson & Johnson, 06 November 2026

More top stories